AMLX

Amylyx Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

8.010

+0.02(0.250%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.020

Open

8.000

VWAP

Vol

290.18K

Mkt Cap

712.24M

Low

7.840

Amount

EV/EBITDA(TTM)

Total Shares

68.01M

508.17M

EV/OCF(TTM)

P/S(TTM)

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

0.00

-100%

0.00

-100%

0.00

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Amylyx Pharmaceuticals, Inc. (AMLX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 63.47%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+63.47%

In Past 3 Month

8 Analyst Rating

51.94% Upside

Wall Street analysts forecast AMLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMLX is 12.17 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

51.94% Upside

Current: 8.010

Low

8.00

Averages

12.17

High

17.00

51.94% Upside

Current: 8.010

Low

8.00

Averages

12.17

High

17.00

Goldman Sachs

NULL

Buy

initiated

$10

2025-07-10

Reason

Goldman Sachs

Price Target

$10

2025-07-10

initiated

NULL

Buy

Reason

Goldman Sachs resumed coverage of Amylyx with a Buy rating and $10 price target, suggesting 58% upside. The firm has a positive view on avexitide for the treatment of post-bariatric surgery hypoglycemia. It sees a potential blockbuster opportunity.

Guggenheim

Seamus Fernandez

initiated

$17

2025-06-24

Reason

Guggenheim

Seamus Fernandez

Price Target

$17

2025-06-24

initiated

Reason

Guggenheim analyst Seamus Fernandez initiated coverage of Amylyx with a Buy rating and $17 price target.

Guggenheim

initiated

$17

2025-06-24

Reason

Guggenheim

Price Target

$17

2025-06-24

initiated

Reason

Citi

Geoff Meacham

Buy

initiated

$12

2025-06-18

Reason

Citi

Geoff Meacham

Price Target

$12

2025-06-18

initiated

Buy

Reason

TD Cowen

initiated

2025-05-30

Reason

TD Cowen

Price Target

2025-05-30

initiated

Reason

TD Cowen initiated coverage of Amylyx with a Buy rating and no price target. The company's lead asset avexitide is a GLP-1 receptor antagonist in development for post-bariatric hypoglycemia, the analyst tells investors in a research note. The firm says its key opinion leaders are optimistic for Phase III success and eventual uptake based on the prior Phase II data. TD sees Amylyx shares as undervalued for the potential of avexitide in post-bariatric hypoglycemia alone.

Mizuho

Outperform

upgrade

$7 -> $8

2025-05-14

Reason

Mizuho

Price Target

$7 -> $8

2025-05-14

upgrade

Outperform

Reason

Mizuho raised the firm's price target on Amylyx to $8 from $7 and keeps an Outperform rating on the shares. Following the updated Phase data for AMX0035 in Wolfram syndrome, the firm increased its probability of success to 50% from 30% and now project speak risk-adjusted/risk-unadjusted sales of $174.8M.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amylyx Pharmaceuticals Inc (AMLX.O) is -4.79, compared to its 5-year average forward P/E of 1.95. For a more detailed relative valuation and DCF analysis to assess Amylyx Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

1.95

Current PE

-4.79

Overvalued PE

15.76

Undervalued PE

-11.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

2.65

Current EV/EBITDA

-3.27

Overvalued EV/EBITDA

14.98

Undervalued EV/EBITDA

-9.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

713.05

Current PS

0.00

Overvalued PS

3917.39

Undervalued PS

-2491.30

Financials

Annual

Quarterly

FY2025Q1

YoY :

-100.00%

0.00

Total Revenue

FY2025Q1

YoY :

+27.58%

-37.80M

Operating Profit

FY2025Q1

YoY :

-69.77%

-35.91M

Net Income after Tax

FY2025Q1

YoY :

-76.00%

-0.42

EPS - Diluted

FY2025Q1

YoY :

+7064.57%

-39.84M

Free Cash Flow

FY2025Q1

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q1

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q1

YoY :

-100.00%

N/A

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 173.42% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

295.8K

USD

6-9

Months

198.6K

USD

0-12

Months

183.2K

USD

Bought

0-3

0.0

USD

Months

3-6

37.0K

USD

Months

6-9

0.0

USD

Months

0-12

427.8K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.9M

Volume

Months

6-9

6.4M

Volume

Months

0-12

4.6M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 173.42% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

295.8K

USD

6-9

Months

198.6K

USD

0-12

Months

183.2K

USD

Bought

0-3

0.0

USD

Months

3-6

37.0K

USD

Months

6-9

0.0

USD

Months

0-12

427.8K

USD

Months

AMLX News & Events

Events Timeline

2025-07-13 (ET)

2025-07-13

20:11:13

Amylyx presents new analyses from Phase 2, Phase 2b trials of avexitide

2025-06-03 (ET)

2025-06-03

07:03:39

Amylyx receives fast track designation for AMX0114 from FDA

2025-05-12 (ET)

2025-05-12

07:06:27

Amylyx announces results from Phase 2 HELIOS trial of AMX0035

News

9.0

07-14Benzinga

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

7.0

07-14Globenewswire

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

7.0

07-07Globenewswire

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm